Thromboembolic diseases of childhood

Blood Reviews

Volumn 17, Issue 1, 2003, Pages 1-6

  Revel Vilk, S ^a   Massicotte, P ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Children; Diagnosis; Risk factors; Thromboembolic events; Treatment

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; DANAPAROID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMIN; PLASMINOGEN; PROTEIN KINASE C; WARFARIN;

ALOPECIA; AORTA ARCH SYNDROME; ARTICLE; BLEEDING; CALCIFICATION; CENTRAL VENOUS CATHETER; CEREBROVASCULAR ACCIDENT; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DISEASE COURSE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FAMILY HISTORY; HUMAN; LABORATORY DIAGNOSIS; LONG TERM CARE; LUNG EMBOLISM; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SIDE EFFECT; SINUS VENOSUS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA; TRACHEA DISEASE;

EID: 0037363636     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(02)00007-3     Document Type: Article

References (97)

1. Andrew M, Michelson AD, Bovill T et al. The prevention and treatment of thromboembolic disease in children: a need for thrombophilia programs. J Pediatr Hematol Oncol 1997; 19: 7-22.
2. Streif W, Andrew ME. Venous thromboembolic events in pediatric patients. Diagnosis and management. Hematol Oncol Clin North Am 1998; 12: 1283-1312.
3. Andrew M, David M, deVeber G, Brooker LA. Arterial thromboembolic complications in paediatric patients. Thromb Haemost 1997; 78: 715-725.
4. Andrew M, David M, Adams M et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83: 1251-1257.
5. van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heiimans HSA, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001; 139: 676-681.
6. Monagle P, Adams M, Mahoney M et al. Outcome of pediatric thromboembolic disease: a report from the Canadian childhood thrombophilia registry. Pediatr Res 2000; 47: 763-766.
7. Prandoni P, Lensing WA, Cogo A et al. The long term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
8. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995; 96: 939-943.
9. Nowak-Göttl U, von Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997; 76: F163-F167.
10. Heller C, Schobess R, Kurnik K et al. Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. Br J Haematol 2000; 111: 534-539.
11. Bokenkamp A, von Kries R, Nowak-Göttl U, Gobel U, Hoyer PF. Neonatal renal venous thrombosis in Germany between 1992 and 1994: epidemiology, treatment and outcome. Eur J Pediatr 2000; 159: 44-48.
12. Adcock D, Hicks MJ. Dermatopathology of skin necrosis associated with purpura fulminants. Semin Thromb Haemost 1990; 69: 283-292.
13. Auletta MJ, Headington JT. Purpura fulminans: a cutaneous manifestation of severe protein C deficiency. Arch Dermatol 1988; 124: 1387-1391.
14. Berube C, Mitchell L, Silverman E et al. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study. Pediatr Res 1998; 44: 351-356.
15. Vandenbroucke JP, Rosing J, Bloemenkamp KWM et al. Medical progress: oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-1535.
16. Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost 1997; 23: 271-280.
17. Borgna-Pignatti C, Carnelli V, Caruso V et al. Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol 1998; 99: 76-79.
18. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian registry of venous thromboembolic complications. J Pediatr 1998; 133: 770-776.
19. Andrew M, Marzinotto V, Pencharz P et al. A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. J Pediatr 1995; 126: 358-363.
20. Talbott GA, Winters WD, Bratton SL, O'Rourke PP. A prospective study of femoral catheter-related thrombosis in children. Arch Pediatr Adolesc Med 1995; 149: 288-291.
21. Beck C, Dubois J, Grignon A, Lacroix J, David M. Incidence and risk factors of catheter related deep vein thrombosis in a pediatric intensive care unit: a prospective study. J Pediatr 1998; 133: 237-241.
22. Mitchell L, Abshire T, Hanna K, Andrew M, for the PARKAA investigators. A prospective cohort determinating the incidence of thrombotic events in children with acute lymphoblastic leukemia treated with L-asparginase: results of the PARKAA study. Blood 1999; 94: 649a.
23. Mitchell L, Chait P, Ginsberg J, Hanna K, Andrew M. Comparison of venography with ultrasound for detection of venous thrombosis in the upper body in children: results of the PARKAA study. Blood 1999; 94: 588a.
24. Andrew M, PROTEKT Investigators. A randomized control trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: The PROTEKT trial. Blood 2000; 96: 492a.
25. Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med 2000; 26: 967-972.
26. Freed M, Keane J, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutanous cardiac catheterization in children. Circulation 1974; 50: 565-569.
27. Hentschel R, Wiescholek U, von Lengerke J, Harms E, Jorch G. Coagulation-associated complications of indwelling arterial and central venous catheters during heparin prophylaxis - a prospective study. Eur J Pediatr 1999; 158(Suppl. 3): S126-S129.
28. Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 2001; 119: S344-S370.
29. Sade RM, Crawford Jr FA, Fyfe DA, Stroud MR. Valve prostheses in children: a reassessment of anticoagulation. J Thorac Cardiovasc Surg 1988; 95: 553-561.
30. Solymar L, Rao PS, Mardini MK, Fawzy ME, Guinn G. Prosthetic valves in children and adolescents. Am Heart J 1991; 121: 557-568.
31. deVeber G, Andrew M. Canadian Pediatric lschemic Stroke Study Group. Cerebral sinovenous thrombosis in children. N Engl J Med 2001; 345: 417-423.
32. Lancon JA, Killough KR, Tibbs RE, Lewis AI, Parent AD. Spontaneous dural sinus thrombosis in children. Pediatr Neurosurg 1999; 30: 23-29.
33. Bonduel M, Sciuccati G, Hepner M, Torres AF, Pieroni G, Frontroth JP. Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis. Arch Neurol 1999; 56: 967-971.
34. Veilhaber H, Ehrenforth S, Koch HG, Scharrer I, van der Werf N, Nowak-Göttl U. Cerebral venous sinus thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia. Eur J Pediatr 1998; 157: 555-560.
35. Heller C, Becker S, Scharrer I, Kreuz W. Prothrombotic risk factors in childhood stroke and venous thrombosis. Eur J Pediatr 1999; 158(Suppl. 3): S117-S121.
36. Schoenberg BS, Mellinger JF, Schoenberg DF. Cerebrovascular disease in infants and children: a study of incidence, clinical features, and survival. Neurology 1978; 28: 763-768.
37. Broderick J, Talbot TG, Prenger E, Leach A, Brott T. Stroke in children within a major metropolitan area: the surprising importance of intracereblar hemorrhage. J Child Neurol 1993; 8: 250-255.
38. deVeber G, Monagle P, Chan A et al. Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurol 1998; 55: 1539-1543.
39. Becker S, Heller C, Gropp F, Scharrer I, Kreuz W. Thrombophilic disorders in children with cerebral infarction. Lancet 1998; 352: 1756-1757.
40. Askalan R, Laughlin S, Mayank S et al. Chickenpox and stroke in childhood: a study of frequency and causation. Stroke 2001; 1257-1262.
41. Chabrier S, Husson B, Lasjaunias P, Landrieu P, Tardieu M. Stroke in childhood: outcome and recurrence risk by mechanism in 59 patients. J Child Neurol 2000; 15: 290-294.
42. Yap S, Naughten ER, Wilcken B, Wilcken DE, Boers GH. Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy. Semin Thromb Hemost 2000; 26: 335-340.
43. Zenz W, Bodo Z, Plotho J et al. Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke. Thromb Haemost 1998; 80: 763-766.
44. Kenet G, Sadetzki S, Murad H et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000; 31: 1283-1288.
45. Nowak-Göttl U, Strater R, Heinecke A et al. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999; 94: 3678-3682.
46. Lanthier S, Carmant L, David M, Larbrisseau A, de Veber G. Stroke in children: the coexistence of multiple risk factors predicts poor outcome. Neurology 2000; 54: 371-378.
47. deVeber GA, MacGregor D, Curtis R, Mayank S. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurol 2000; 15: 316-324.
48. Lane DA, Mannucci PM, Bauer KA et al. Inherited thrombophilia: part I. Thromb Haemost 1996; 76: 651-662.
49. Pineo GF, Hull RD. Thrombophilia: disorders predisposing to venous thromboembolism. Baill Clin Haematol 1998; 11: 525-540.
50. Michiels JJ, Hamulyak K. Laboratory diagnosis of hereditary thrombophilia. Semin Thromb Hemost 1998; 24: 309-320.
51. Gaustadnes M, Rudiger N, Moller J, Rasmussen K, Bjerregaard Larsen T, Ingerslev J. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. Blood Coagul Fibrinolysis 1999; 10: 251-259.
52. von Depka M, Nowak-Göttl U, Elsert R et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000; 96: 3364-3368.
53. Kraaijenhagen RA, Anker PS, Koopman MMW et al. High plasma concentration of factor VIIIc is a major risk factors for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
54. Meijers JCM, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.
55. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95: 3678-3682.
56. Lawson SE, Butler D, Enayat MS, Williams MD. Congenital thrombophilia and thrombosis: a study in a single center. Arch Dis Child 1999; 81: 176-178.
57. Ehrenfoth S, Junker R, Koch HG et al. Multicenter evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Eur J Pediatr 1999; 158(suppl 3): S97-104.
58. Hagstrom JN, Walter J, Bluebond-Langner R, Amatniek JC, Manno CS, High KA. Prevalence of the factor V leiden mutation in children and neonates with thromboembolic disease. J Pediatr 1998; 133: 777-781.
59. Bonduel M, Hepner M, Sciuccati G, Torres AF, Pieroni G, Frontroth JP. Prothrombotic abnormalities in children with venous thromboembolism. J Pediatr Hematol Oncol 2000; 22: 66-72.
60. Revel-Vilk S, Chan A, Knapp C et al. Incidence of congenital prothrombotic disorders in children with venous thromboembolic disease: a prospective cohort study. Blood 2001; 98: 50a.
61. Wermes C, von Depka-Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora KW. Clinical relevance of gentic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999; 158(Suppl. 3): S143-S146.
62. Nowak-Göttl U, Dubbers A, Kececioglu D et al. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study. J Pediatr 1997; 131: 608-612.
63. Kosch A, Junker R, Kurnik K et al. Prothrombotic risk factors in children with spontaneous venous thrombosis and their asymptomatic parents: a family study. Thromb Res 2000; 99: 531-537.
64. Nowak-Göttl U, Junker R, Kreuz W et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97: 858-862.
65. Manco-Johnson MJ. Disorders of hemostasis in childhood: risk factors for venous thromboembolism. Thromb Haemost 1997; 78: 710-714.
66. Segel GB, Francis CA. Anticoagulant proteins in childhood venous and arterial thrombosis: a review. Blood Cells Mol Dis 2000; 26: 540-560.
67. Chan AK, deVeber G. Prothrombotic disorders and ischemic stroke in children. Semin Pediatr Neurol 2000; 7: 301-308.
68. Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin Chem 2001; 47: 1597-1606.
69. Martinelli I, Mannucci PM, De Stefano V et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-2358.
70. Bucciarelli R, Rosendaal FR, Tripodi A et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999; 19: 1026-1033.
71. Simioni P, Sanson BJ, Pradoni P et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202.
72. Sanson BJ, Simioni P, Tormene D et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C or protein S: a prospective cohort study. Blood 1999; 94: 3702-3706.
73. Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 2000; 51: 169-185.
74. Sutor AH, Uhl M. Diagnosis of thromboembolic disease during infancy and childhood. Semin Thromb Hemost 1997; 23: 237-246.
75. Anton N, Massicotte P. Venous thromboembolism in pediatrics, Semin Vasc Med 2001; 1: 111-121.
76. Hirsh J, Warkentin TE, Shaughnessy SG et al, Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: S64-S94.
77. Andrew M, Mitchell L, Vegh R, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost 1994; 72: 836-842.
78. Streif W, Mitchell LG, Andrew M. Antithormbotic therapy in children. Curr Opin Pediatr 1999; 11: 56-64.
79. Andrew M, Marzinotto V, Massicotte P et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994; 35: 78-83.
80. Ranze O, Ranze P, Magnani HN, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients - a review of the literature and a new case treated with dansproid sodium. Eur J Pediatr 1999; 158(suppl 3): S130-S133.
81. Avioli L. Heparin induced osteoporosis: an appraisal. Adv Exp Med Biol 1975; 52: 375-387.
82. Dix D, Andrew M, Marzinotto V et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000; 136: 439-445.
83. Punzalan RC, Hillery CA, Montgomery RR, Scott JP, Gill JC. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 2000; 22: 137-142.
84. Weitz JI. Low molecular weight heparins. N Engl J Med 1997; 337: 688-698.
85. Hirsh J, Dalen JE, Anderson DR et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: S8-S21.
86. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food, Ann Intern Med 1994; 121: 676-683,
87. Andrew M, Marzinotto V, Brooker LA et al. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost 1994; 71: 265-269.
88. Streif W, Andrew M, Marzinotto V et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 1999; 94: 3007-3014.
89. Schmidt B, Andrew M. Report of scientific and standardization subcommittee on neonatal hemostasis diagnosis and treatment of neonatal thrombosis, Thromb Haemost 1992; 67: 381-382.
90. Marzinotto V, Monagle P, Chan A et al. Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting. Pediatr Cardiol 2000; 21: 347-352.
91. Hooshang T, Capitanio M. Tracheobronchial calcification: an observation in three children after mitral valve replacement and warfarin sodium therapy. Radiology 1990; 176: 728-730.
92. Massicotte P, Julian J, Webber C, Charpentier K. Osteoporosis: a potential complication of long term warfarin therapy. Thromb Haemost 1999; Suppl.: 1333a.
93. Chalmers EA, Gibson BE. Thrombolytic therapy in the management of paediatric thromboembolic disease. Br J Haematol 1999; 104: 14-21.
94. Robinson A, Fellows KE, Bridges ND, Rome JJ. Effectiveness of pharmacomechanical thrombolysis in infants and children. Am J Cardiol 2001; 87: 496-499.
95. Choi M, Massicotte MP, Marzinotto V, Chan AK, Holmes JL, Andrew M. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study. J Pediatr 2001; 139: 152-156.
96. Leaker M, Massicotte MP, Brooker LA, Andrew M, Thrombolytic therapy in pediatric patients: a comprehensive review of the literature. Thromb Haemost 1996; 76: 132-134.
97. Gupta AA, Leaker M, Andrew M et al. Safety and outcome of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr 2001; 139: 682-688.